Search Bar & Filters
Found 35 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC that has returned after prior therapy. The study aims to find out if the combination of belzutifan and zanzalintinib can help people with recurrent advanced RCC live longer without their cancer worsening compared to the drug cabozantinib. This is a phase 3 randomized trial evaluating these treatments in participants who have experienced recurrence during or after prior anti-PD-1L1 therapy. Participants are randomly assigned to receive either belzutifan plus zanzalintinib taken orally once daily or cabozantinib taken orally once daily. They continue their assigned treatment until certain reasons require stopping the study intervention. The study compares the effects of these treatments on cancer progression and survival among people with advanced RCC who have had disease recurrence after adjuvant therapy. During the study, participants will be regularly monitored for progression-free survival and overall survival for up to about 73 months. Researchers will also assess tumor response, duration of response, adverse events, and quality of life using questionnaires over approximately 25 months. The study involves ongoing evaluations to understand how these treatments affect symptoms, functioning, and overall health during long-term follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
This research aims to compare overall survival in men with chemotherapy-naefve metastatic castration-resistant prostate cancer. The study evaluates the combination of xaluritamig and abiraterone against the investigators choice of treatments, which include abiraterone, docetaxel, or cabazitaxel. The trial is a phase 3, open-label, randomized study sponsored by Amgen. Participants will be randomly assigned to receive either xaluritamig administered intravenously combined with oral abiraterone acetate, or the investigators choice of one of the following treatments daily oral abiraterone acetate, or intravenous docetaxel or cabazitaxel given every three weeks. Treatments continue with regular monitoring throughout the study period, which lasts up to approximately 51 months for outcome assessments. Participants will undergo various assessments including imaging scans such as CT, MRI, or bone scans to confirm metastatic disease and monitor progression. Researchers will also evaluate pain levels, quality of life, prostate-specific antigen PSA responses, and adverse events throughout the study. Follow-up evaluations will continue for up to 51 months to measure survival and other health outcomes, with safety monitoring conducted throughout the participation period.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combination therapy called BMS-986489 Atigotatug plus Nivolumab with Carboplatin and Etoposide compared to Atezolizumab with Carboplatin and Etoposide. This study focuses on participants with extensive-stage small cell lung cancer to understand which treatment works better as a first-line therapy. It is a Phase 3 clinical trial led by Bristol-Myers Squibb. Participants are randomly assigned to one of two groups one receiving the BMS-986489 combination with Carboplatin and Etoposide, and the other receiving Atezolizumab with Carboplatin and Etoposide. All medications are given at specific doses on designated days. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants undergo regular assessments including imaging scans to measure tumor size, and evaluations of overall survival over up to five years. Researchers also monitor symptoms, response duration, progression-free survival, and any adverse or serious side effects up to 135 days after treatment ends. The study includes detailed safety and efficacy tracking with multiple outcome measures to fully understand the impact of each treatment option.
Actively Recruiting
Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.
Actively Recruiting
Researchers are investigating the efficacy of divarasib compared with the investigators choice of immunotherapy pembrolizumab or nivolumab or observation in adults with resected Stage II-IIIB non-small cell lung cancer NSCLC that tests positive for the KRAS G12C mutation. This study focuses on participants who have not achieved a complete pathological response following neoadjuvant chemoimmunotherapy, regardless of tumor PD-L1 status. The trial aims to assess disease-free survival and overall survival in this patient group. Participants will be randomly assigned to one of two groups. One group will receive divarasib orally once daily for up to 52 cycles, each cycle lasting 21 days. The other group will receive either pembrolizumab or nivolumab immunotherapy, administered according to prior treatment type, or will be observed without study treatment. Pembrolizumab is given as an intravenous infusion every three weeks or a subcutaneous injection every three weeks for up to 13 cycles. Nivolumab is given as an intravenous infusion or subcutaneous injection every four weeks for up to 13 cycles. Observation participants will not receive any study treatment. Throughout the study, participants will be monitored for disease recurrence or death for up to approximately five years to assess disease-free survival. Additional outcomes include overall survival for up to eight years, adverse events tracking up to 60 days after treatment ends, and disease-free survival rates at two and three years. Participants will undergo regular evaluations to monitor their health status and study outcomes. The total duration of participation may extend up to eight years from randomization.
1-10 of 35
1